Drug Delivery Across ENT Barriers: Mechanisms, Challenges, and Clinical Strategies

Abstract

Effective drug delivery across ear, nose, and throat (ENT) barriers remains a clinical challenge due to unique anatomical and physiological properties. This article provides a comprehensive review of current evidence and practical strategies for optimizing drug delivery in ENT disorders, focusing on mechanisms, clinical features, innovations, and guideline-based recommendations. Recent advances, risks, and future directions are discussed to inform evidence-based practice for healthcare professionals.

Introduction

ENT disorders, encompassing diseases of the ear, nose, and throat, are prevalent globally and significantly impact quality of life. Therapeutic efficacy in these conditions is often limited by the anatomical and physiological barriers intrinsic to the upper aerodigestive tract. Overcoming these barriers is critical for achieving optimal drug concentrations at the target site, reducing systemic exposure, and minimizing adverse effects. This review aims to elucidate the mechanisms, challenges, and advances in drug delivery across ENT barriers, providing clinicians with a practical and evidence-based resource.

Epidemiology / Disease Burden

ENT disorders such as chronic rhinosinusitis, allergic rhinitis, otitis media, and pharyngitis affect millions worldwide, contributing to significant morbidity and healthcare utilization. Chronic rhinosinusitis alone affects approximately 12% of the adult population, while otitis media is a leading cause of pediatric physician visits. The burden is compounded by recurrent symptoms, antibiotic resistance, and the need for repeated interventions, underscoring the importance of effective local drug delivery strategies.

Pathophysiology

The ENT region comprises complex mucosal barriers, ciliated epithelium, mucus layers, and tight junctions, all of which regulate the passage of therapeutic agents. Pathological changes—such as inflammation-induced hypersecretion, epithelial damage, or altered mucociliary clearance—further complicate drug penetration. Understanding these mechanisms is essential for designing delivery systems that can traverse barriers and achieve therapeutic concentrations at diseased sites.

Risk Factors

Risk factors influencing the success of ENT drug delivery include patient age, comorbidities (e.g., cystic fibrosis, immunodeficiency), anatomical variations (e.g., deviated septum, adenoid hypertrophy), and disease chronicity. Additionally, previous surgeries, biofilm formation, and genetic predispositions can alter drug absorption and retention, necessitating individualized treatment approaches.

Clinical Features

Clinical manifestations of ENT disorders—such as nasal congestion, rhinorrhea, otalgia, hearing loss, sore throat, and dysphagia—may influence the choice and mode of drug delivery. For example, severe mucosal edema in allergic rhinitis can hinder topical drug absorption, while tympanic membrane perforation in otitis media may facilitate unintended systemic exposure. Recognizing these features guides clinicians in selecting optimal delivery routes and formulations.

Diagnosis

Accurate diagnosis relies on thorough history, clinical examination, endoscopy, audiometry, imaging, and laboratory investigations. Objective assessment of mucosal integrity and disease severity can inform the likelihood of successful local therapy and the potential need for adjunctive systemic treatment. Diagnostic innovations, such as imaging of drug distribution and mucociliary function, are increasingly utilized in research settings to evaluate delivery efficacy.

Treatment & Management

Drug delivery strategies in the ENT region include topical nasal sprays, drops, irrigations, inhalers, and systemic therapies. Topical delivery minimizes systemic exposure and maximizes local effect but requires overcoming mucosal barriers and achieving uniform distribution. Nasal sprays (e.g., corticosteroids, antihistamines) are first-line in allergic rhinitis, while topical antibiotics and steroids are frequently used in otitis externa and chronic rhinosinusitis. Systemic therapies are reserved for severe or refractory cases but carry higher risk of adverse effects.

Recent Advances / Emerging Therapies

Recent innovations focus on enhancing drug penetration and retention at target sites. Nanoparticle-based carriers, mucoadhesive formulations, and thermoresponsive gels have demonstrated improved mucosal absorption and sustained release in preclinical and early clinical studies. Advances in intratympanic and intranasal delivery devices, such as atomizers and pressure-assisted applicators, offer promise for more precise targeting and reduced systemic exposure. Biologics, including monoclonal antibodies for chronic rhinosinusitis with nasal polyps, represent a paradigm shift in the management of refractory disease.

Guideline Recommendations

Clinical practice guidelines recommend tailored drug delivery based on disease severity, anatomical considerations, and patient preferences. For chronic rhinosinusitis, intranasal corticosteroids are recommended as first-line, with adjunctive saline irrigations. Otitis media management emphasizes topical over systemic antibiotics when feasible, and judicious use of systemic agents to limit resistance. Adherence to guideline-based delivery methods is associated with improved outcomes and reduced complications.

Conclusion

Optimizing drug delivery across ENT barriers requires a nuanced understanding of anatomy, pathophysiology, and patient-specific factors. Recent advances in formulation science, device technology, and biologic therapies are expanding the therapeutic arsenal available to clinicians. Evidence-based, individualized strategies are essential for maximizing efficacy and minimizing adverse effects, ultimately improving patient outcomes in ENT disorders.